Mucor Mycosis in COVID-19: Case Reports | Zendy

Kavita Upadhyay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mucor Mycosis in COVID-19: Case Reports

Author(s) -

Kavita Upadhyay

Publication year - 2020

Publication title -

journal of advanced research in medicine

Language(s) - English

Resource type - Journals

eISSN - 2394-7047

pISSN - 2349-7181

DOI - 10.24321/2349.7181.202016

Subject(s) - mucormycosis , covid-19 , pathogenesis , monoclonal antibody , microbiology and biotechnology , immunology , antibiotics , mucor , coronavirus , mycosis , medicine , biology , disease , virology , antibody , pathology , infectious disease (medical specialty) , aspergillus

Coronavirus infections are associated with a wide range of bacterial and fungal co-infections. Use of steroids, monoclonal antibodies and broad spectrum antibiotics along with underlying pathogenesis may alter body homeostasis and exacerbate preexisting fungal disease. We report the cases with COVID-19 infection, which, after the course of the treatment, presented with various forms of mucormycosis infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research